Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction Cancer patients on active treatment are at increased risk of developing coronavirus disease 2019 (COVID-19), making effective immunization of the utmost importance. However, the effectiveness of vaccination in this population is still unclear. This study aims to evaluate the response against COVID-19 in a cohort of patients with active cancer under immunosuppressive therapy. Methods This was a prospective, cross-sectional, single-center study that included patients with cancer under immunosuppressive therapy vaccinated against COVID-19 between April and September 2021. Exclusion criteria were: previous known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, single-dose vaccine or incomplete vaccination scheme. Immunoglobulin G (IgG) anti-SARS-CoV-2 antibody levels were assessed using 35.2 binding antibody units (BAU)/mL as the positive cut-off. Assessments were performed 14-31 days after the first and second dose and three months after the second dose. Results A total of 103 patients were included. The median age was 60 years. Most patients were being treated for gastrointestinal cancer (n=38, 36.9%), breast cancer (n=33, 32%) or head and neck cancer (n=18, 17.5%). At evaluation, 72 patients (69.9%) were being treated with palliative intent. The majority were being treated with chemotherapy (CT) alone (57.3%). At the first assessment, levels of circulating SARS-CoV-2 IgG consistent with seroconversion were present in 49 patients (47.6%). At the time of the second assessment, 91% (n=100) achieved seroconversion. Three months after the second dose, 83% (n=70) maintained levels of circulating SARS-CoV-2 IgG consistent with seroconversion. In this study, no SARS-CoV-2 infection was reported in the study population. Conclusions Our findings suggest that this group of patients had a satisfactory COVID-19 immunization response. Although promising, this study should be replicated on a wider scale in order to validate these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151022 | PMC |
| http://dx.doi.org/10.7759/cureus.37014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma].
Vestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).
Brucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating the NF-κB Signaling Pathway.
J Biochem Mol Toxicol
September 2025
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, PR China.
Gastric cancer (GC) is the third leading cause of cancer mortality globally, often presenting with insidious symptoms that lead to late-stage diagnoses, underscoring the critical need for innovative diagnostic and therapeutic strategies. One such avenue is the exploration of ferroptosis, a regulated form of cell death implicated in various pathological conditions and malignancies. In this study, we demonstrate that brucine, an alkaloid derived from Strychnos nux-vomica, exerts significant antitumor effects on GC cells both in vitro and in vivo.
View Article and Find Full Text PDFGlucocorticoid Alleviates Stress-induced Hypothalamic Nerve Injury by Inhibiting the GSDMD-dependent Pyroptosis Pathway.
J Integr Neurosci
August 2025
Xinxiang Key Laboratory of Forensic Toxicology, School of Forensic Medicine, Xinxiang Medical University, 453003 Xinxiang, Henan, China.
Background: Excessive stress leads to stress injury but the underlying mechanism is not completely understood and current preventive protocols are inadequate. This study aimed to investigate if glucocorticoid (GC) reduces nerve damage in the hypothalamus caused by stress and to clarify the mechanisms involved.
Methods: Behavioral alterations in stressed rats were observed using the open field test.
Immunogenicity comparison of an -produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
Lancet Reg Health West Pac
September 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.
Background: Cecolin9, a second-generation 9-valent HPV vaccine derived from the WHO-prequalified Cecolin, has received marketing authorisation in China in May 2025. The non-inferiority of type-specific immune responses between Cecolin9 and Gardasil9 has been previously established at month 7 in Chinese women aged 18-26 years (NCT04782895). This study aimed to compare the plateau antibody levels between the two vaccines three years post the first dose.
View Article and Find Full Text PDFEvaluation of the liver load index as a predictor of liver exposure in right breast radiotherapy.
Rep Pract Oncol Radiother
August 2025
Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Background: To compare doses deposited to the liver during right breast radiotherapy with static and dynamic radiotherapy techniques. The second aim was to introduce the liver load index (LLI), a novel index developed to estimate radiation exposure to the liver prior to treatment selection.
Materials And Methods: We prepared radiotherapy treatment plans for ten patients with right breast cancer.